<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82418">
  <stage>Registered</stage>
  <submitdate>14/11/2007</submitdate>
  <approvaldate>19/11/2007</approvaldate>
  <actrnumber>ACTRN12607000592448</actrnumber>
  <trial_identification>
    <studytitle>Is cotrimoxazole safe and efficacious for treatment of skin sores in Aboriginal children: a pilot study</studytitle>
    <scientifictitle>In Aboriginal children in remote communities, is oral cotrimoxazole as safe and efficacious as intramuscular benzathine penicillin, in achieving resolution of skin sores?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Impetigo</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral cotrimoxazole 4+20 mg/kg (up to 160/800mg) twice daily for 5 days</interventions>
    <comparator>Intramuscular benzathine penicillin 45mg/kg (up to 900mg) as a single dose</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Successful treatment (healed or improved) of skin sores</outcome>
      <timepoint>Day 7 after commencement of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bacterial resolution of skin sores</outcome>
      <timepoint>Day 4 and 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evidence of allergy or other adverse effect to study medications</outcome>
      <timepoint>Up till day 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of purulent or crusted impetigo.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.  Receipt of any antibiotic in the previous seven days, or receipt of benzathine penicillin in the previous 30 days. 
2.  The presence of impetigo lesions that are only flat-dry (i.e. lesions that are not purulent or crusted)
3.  Known allergy to penicillin, sulphonamide drugs or trimethoprim, or other constituents of study medications. 
4.  Immunocompromised. 
5.  Acute or chronic dermatosis. 
6.  Evidence of sepsis, cellulitis, bullous impetigo, boils or carbuncles.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>We will recruit children from households in a remote Aboriginal community. Households will be screened for children with skin sores. Eligible children with impetigo, and their parents/guardians, will be approached for written, informed consent.
Eligible  children  will  be  randomised  by  the  use  of  sealed,  sequentially  marked, 
opaque envelopes  in  accordance  with  the  CONSORT  statements. Randomisation will be by permuted block randomisation.</concealment>
    <sequence>Permuted block randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>0810</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Menzies School of Health Research</primarysponsorname>
    <primarysponsoraddress>PO Box 41096
Casuarina NT 0811</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Menzies School of Health Research</fundingname>
      <fundingaddress>PO Box 41096
Casuarina NT 0811</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aim to conduct a pilot study to determine the efficacy and safety of oral cotrimoxazole compared to benzathine penicillin (BPG), for the treatment of skin sores(also known as impetigo) in children living in a remote Aboriginal community in the Northern Territory. Cotrimoxazole may be a much more acceptable oral alternative compared to the uncomfortable and poorly received intramuscular benzathine penicillin which is the current standard of care.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Territory Department of Health and Community Services and Menzies School of Health Research</ethicname>
      <ethicaddress>Menzies School of Health Research</ethicaddress>
      <ethicapprovaldate>12/12/2007</ethicapprovaldate>
      <hrec>07/84</hrec>
      <ethicsubmitdate>14/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven Tong</name>
      <address>PO Box 41096
Casuarina NT 0811</address>
      <phone>+61 8 89228196</phone>
      <fax />
      <email>steven.tong@menzies.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Steven Tong</name>
      <address>PO Box 41096
Casuarina NT 0811</address>
      <phone>+61 8 89228196</phone>
      <fax />
      <email>steven.tong@menzies.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Steven Tong</name>
      <address>PO Box 41096
Casuarina NT 0811</address>
      <phone>+61 8 89228196</phone>
      <fax />
      <email>steven.tong@menzies.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>